Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia-Reference-Cited by-同舟云学术

Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia

Published:2024-06-19 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mingot‐Castellano Maria Eva¹^ORCID,Bastida Jose Maria²,Ghanima Waleed³,Ruiz Sainz Elena⁴,Nuñez Vazquez Ramiro¹,Pedrote Amador Begoña¹,Abdel‐Kader Martín Laila⁵,Piquer‐Monsonis Dolores⁶,Canaro Mariana⁶

Affiliation:

1. Hematology Department Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS /CSIC), Universidad de Sevilla Sevilla Spain

2. Hematology Department Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL) Salamanca Spain

3. Department of Research and Haemato‐Oncology Østfold Hospital and Institute of Clinical Medicine, University of Oslo Oslo Norway

4. Hematology Department Hospital del Tajo Aranjuez Madrid Spain

5. Pharmacy Department Hospital Universitario Virgen del Rocio Sevilla Spain

6. Hematology Department Hospital Son Espases Mallorca Spain

Abstract

SummaryImmune thrombocytopenia (ITP) refractory to multiple therapies may require a combination of drugs targeting different mechanisms and targets. In this retrospective, multicentre, international study, we report the safety and effectiveness of avatrombopag and fostamatininb in combination administered to 18 patients with multirefractory ITP. Overall, the combination response was achieved in 15 patients (83.3%), with a median time from combination start to best response of 15 days (IQR: 8–35 days). After a median follow‐up of 256 days (IQR: 142.8–319), 5 patients relapsed (26.7%), all during tapering or stopping one drug. Adverse events were described in 6 of 18 patients (33%).

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19602

Reference10 articles.

1. Refractory immune thrombocytopenia in adults: Towards a new definition

2. Difficult‐to‐treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN‐France registry

3. Novel therapeutics and future directions for refractory immune thrombocytopenia

4. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

5. Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience